Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Characteristics of Amphetamine Psychosis with Respect to the Length of Drug Exposure

Author(s): Anastasia Babina, Iryna Sokolova* and Mykhailo Vysotskyi

Volume 22, Issue 4, 2023

Published on: 29 August, 2022

Page: [599 - 606] Pages: 8

DOI: 10.2174/1871527321666220726141936

open access plus

Abstract

Background: Over the past decade, the number of individuals requiring medical care for amphetamine-related psychosis has increased.

Objective: This study aims to examine the psychological characteristics of amphetamine psychosis in drug-addicted patients depending on the length of drug exposure and compared to patients diagnosed with paranoid schizophrenia.

Methods: The study was carried out in psychiatric clinic No. 1 in Kyiv (Ukraine) in 2019, involving 107 patients. Of all the participants, 50 were included in Group 1 (methamphetamine psychosis) and 57 - in Group 2 (paranoid schizophrenia). All patients were treated with medication to relieve exacerbating symptoms. They underwent extensive testing to determine the impairment severity of cognitive function, attention, and task performance during remission.

Results: In Group 1, the timing of onset for paranoid symptoms depends on the length of amphetamine exposure (Spearman correlation coefficient = 0.89). The efficacy and dynamics of drug treatment in Group 2 were similar to patients in Group 1. However, the effect of reduction in Group 2 was achieved only in 4 months. Delusions, emotional disturbances, hallucinations in patients of Group 1 occurred 2.3 times more frequently than in Group 2 (p ≤ 0.05). The patients of Group 1 are characterized by the presence of disorders related to the affective and behavioral components.

Conclusion. All reported exacerbations are related to amphetamine use. Patients in Group 1 learned a smaller number of words compared to those in Group 2. Besides, a large number of errors and difficulties with shifting focus were recorded.

Keywords: Amphetamine, schizophrenia, cognitive function, delusions, hallucinations, amphetamine psychosis.

« Previous Next »
[1]
Unadkat A, Subasinghe S, Harvey RJ, Castle DJ. Methamphetamine use in patients presenting to emergency departments and psychiatric inpatient facilities: What are the service implications? Australas Psychiatry 2019; 27(1): 14-7.
[http://dx.doi.org/10.1177/1039856218810155] [PMID: 30382752]
[2]
Bertol E, Di Milia MG, Fioravanti A, et al. Proactive drugs in DFSA cases: Toxicological findings in an eight-years study. Forensic Sci Int 2018; 291: 207-15.
[http://dx.doi.org/10.1016/j.forsciint.2018.08.032] [PMID: 30218868]
[3]
Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003-2017. MMWR Morb Mortal Wkly Rep 2019; 68(17): 388-95.
[http://dx.doi.org/10.15585/mmwr.mm6817a3] [PMID: 31048676]
[4]
Juchenko LA, Kasimovskaia NA, Yakushina II. The medical genetic counseling and prevention of inborn and congenital pathology in the Russian federation. Problemy Sotsial’noi Gigieny. Zdravookhraneniia i Istorii Meditsiny 2015; 6: 38-40.
[5]
Maev IV, Samsonov AA, Palgova LK, et al. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol 2020; 7(1): e000341.
[http://dx.doi.org/10.1136/bmjgast-2019-000341] [PMID: 32095253]
[6]
Pavlov CS, Casazza G, Semenistaia M, et al. Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev 2016; 3(3): CD011602.
[http://dx.doi.org/10.1002/14651858.CD011602.pub2] [PMID: 26934429]
[7]
Callaghan RC, Halliday M, Gatley J, et al. Comparative hazards of acute myocardial infarction among hospitalized patients with metham-phetamine- or cocaine-use disorders: A retrospective cohort study. Drug Alcohol Depend 2018; 188: 259-65.
[http://dx.doi.org/10.1016/j.drugalcdep.2018.03.030] [PMID: 29793190]
[8]
Dhein S, Schmelmer K, Guenther J, Salameh A. Aspects of methamphetamine abuse in adolescents and young adults in a Thuringian county. Eur Addict Res 2018; 24(2): 98-105.
[http://dx.doi.org/10.1159/000488141] [PMID: 29902793]
[9]
Ma J, Li XD, Wang TY, et al. Relationship between the duration of methamphetamine use and psychotic symptoms: A two-year prospective cohort study. Drug Alcohol Depend 2018; 187: 363-9.
[http://dx.doi.org/10.1016/j.drugalcdep.2018.03.023] [PMID: 29715654]
[10]
Dolan SB, Chen Z, Huang R, Gatch MB. “Ecstasy” to addiction: Mechanisms and reinforcing effects of three synthetic cathinone analogs of MDMA. Neuropharmacology 2018; 133: 171-80.
[http://dx.doi.org/10.1016/j.neuropharm.2018.01.020] [PMID: 29378213]
[11]
Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: A systematic clinical review. Drug Alcohol Depend 2015; 150: 1-13.
[http://dx.doi.org/10.1016/j.drugalcdep.2015.01.040] [PMID: 25724076]
[12]
Härtel-Petri R, Krampe-Scheidler A, Braunwarth WD, et al. Evidence-based guidelines for the pharmacologic management of methamphetamine dependence, relapse prevention, chronic methamphetamine-related, and comorbid psychiatric disorders in post-acute settings. Pharmacopsychiatry 2017; 50(3): 96-104.
[http://dx.doi.org/10.1055/s-0043-105500] [PMID: 28445899]
[13]
Ritchie H, Roser M. Drug use. Our World in Data 2019. https://ourworldindata.org/drug-use
[14]
Rudavka SI. Socio-economic problems of drug addiction in Ukraine and impact of it on health of human. Reports of Vinnytsia National Medical University 2018; 22(4): 752-9.
[http://dx.doi.org/10.31393/reports-vnmedical-2018-22(4)-31]
[15]
Wodarz N, Krampe-Scheidler A, Christ M, et al. Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity. Pharmacopsychiatry 2017; 50(3): 87-95.
[http://dx.doi.org/10.1055/s-0042-123752] [PMID: 28297728]
[16]
Bhatt M, Zielinski L, Baker-Beal L, et al. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: A systematic review and meta-analysis. Syst Rev 2016; 5(1): 189.
[http://dx.doi.org/10.1186/s13643-016-0370-x] [PMID: 27842569]
[17]
Ujike H, Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004; 1025(1): 279-87.
[http://dx.doi.org/10.1196/annals.1316.035] [PMID: 15542728]
[18]
Yeh HS, Lee YC, Sun HJ, Wan SR. Six months follow-up of patients with methamphetamine psychosis. Zhonghua Yi Xue Za Zhi (Taipei) 2001; 64(7): 388-94.
[PMID: 11584576]
[19]
Tselinsky BP. Designer drugs: On the legislative and normativelegal regulation of the fight against illicit trafficking in analogs of narcotic drugs and psychotropic substances. Narconet 2011; 9: 18-24.
[20]
Grelotti DJ, Kanayama G, Pope HG Jr. Remission of persistent methamphetamine-induced psychosis after electroconvulsive therapy: Presentation of a case and review of the literature. Am J Psychiatry 2010; 167(1): 17-23.
[http://dx.doi.org/10.1176/appi.ajp.2009.08111695] [PMID: 20068123]
[21]
Kaklyugin NV. “Synthetic” Russia: Progressive suicide of drug-addicted youth. Problems and prospects. Medicine (Baltimore) 2014; 4: 1-27.
[22]
Fiorentini A, Volonteri LS, Dragogna F, et al. Substance-induced psychoses: A critical review of the literature. Curr Drug Abuse Rev 2011; 4(4): 228-40.
[http://dx.doi.org/10.2174/1874473711104040228] [PMID: 21999698]
[23]
Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69(8): 776-86.
[http://dx.doi.org/10.1001/archgenpsychiatry.2012.169] [PMID: 22474070]
[24]
Smith MJ, Thirthalli J, Abdallah AB, Murray RM, Cottler LB. Prevalence of psychotic symptoms in substance users: A comparison across substances. Compr Psychiatry 2009; 50(3): 245-50.
[http://dx.doi.org/10.1016/j.comppsych.2008.07.009] [PMID: 19374969]
[25]
Jones R, Woods C, Usher K. Rates and features of methamphetamine-related presentations to emergency departments: An integrative literature review. J Clin Nurs 2018; 27(13-14): 2569-82.
[http://dx.doi.org/10.1111/jocn.14493] [PMID: 29679414]
[26]
Wang L, Min JE, Krebs E, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy 2017; 49: 32-40.
[http://dx.doi.org/10.1016/j.drugpo.2017.07.009] [PMID: 28888099]
[27]
Grant KM, LeVan TD, Wells SM, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol 2012; 7(1): 113-39.
[http://dx.doi.org/10.1007/s11481-011-9288-1] [PMID: 21728034]
[28]
Zanelli J, Reichenberg A, Morgan K, et al. Specific and generalized neuropsychological deficits: A comparison of patients with various first-episode psychosis presentations. Am J Psychiatry 2010; 167(1): 78-85.
[http://dx.doi.org/10.1176/appi.ajp.2009.09010118] [PMID: 19952077]
[29]
Murthy P, Chand P. Treatment of dual diagnosis disorders. Curr Opin Psychiatry 2012; 25(3): 194-200.
[http://dx.doi.org/10.1097/YCO.0b013e328351a3e0] [PMID: 22395768]
[30]
Salo R, Ravizza S, Fassbender C. Overlapping cognitive patterns in schizophrenia and methamphetamine dependence. Cogn Behav Neurol 2011; 24(4): 187-93.
[http://dx.doi.org/10.1097/WNN.0b013e31823fc1d0] [PMID: 22123586]
[31]
Davidson SB, Blostein PA, Walsh J, Maltz SB, Elian A, Vanden-Berg SL. Resurgence of methamphetamine related burns and injuries: A follow-up study. Burns 2013; 39(1): 119-25.
[http://dx.doi.org/10.1016/j.burns.2012.03.003] [PMID: 22541621]
[32]
Anderson K. A Model Program for Treating Methamphetamine Use among Adolescents. Alhambra: Alliant International University 2018.
[33]
Bostani D, Karamizadeh A. Condition and strategy of glass consumption among addicted women (case study: Kerman city). Women Develop Politic 2017; 15: 1-20.
[34]
Moheb AH, Qasam A, Mardani S. Measurement of the motivations leading to the use of industrial opiates (case study of caretakers in Qazvin). J Qazvin Law Enforc Quarterly 2016; 5: 114-33.
[35]
Siah Jani L, Orki M, Zare H. Methamphetamine use time (glass) and persistent attention deficit disorders in methamphetamine abusers. J Drug Addic Res 2014; 27: 53-66.
[36]
He J, Xie Y, Tao J, et al. Gender differences in socio-demographic and clinical characteristics of methamphetamine inpatients in a Chinese population. Drug Alcohol Depend 2013; 130(1-3): 94-100.
[http://dx.doi.org/10.1016/j.drugalcdep.2012.10.014] [PMID: 23149112]
[37]
Tsirigotis K. Gender differentiation of indirect self-destructiveness in drug addicted individuals (indirect self-destructiveness in addicted women and men). Psychiatr Q 2019; 90(2): 371-83.
[http://dx.doi.org/10.1007/s11126-019-09629-0] [PMID: 30835014]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy